Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Inclusion Criteria: * Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pelvis, ureter, bladder, prostate, or urethra), with metastatic or locally advanced disease (T4b, N2, N3, or M1); patients must not be candidates for potentially curative surgery or radiotherapy * For patients that have had surgical resection prior to study enrollment, residual or unresected disease (measurable and/or unmeasurable) must be evident on post-surgical scans * Prior treatment for transitional cell carcinoma (TCC) * Patients may not have received combination systemic chemotherapy for metastatic disease * For the purposes of this study, radiosensitizing single agent chemotherapy is not considered prior systemic therapy * Prior neoadjuvant or adjuvant systemic chemotherapy is permissible provided the interval from end of therapy to diagnosis of metastatic disease is at least 1 year * \>= 4 weeks since any prior radiation (including palliative) or major surgery and fully recovered * \>= 7 days since any minor surgery such as port placement * \>= 4 weeks since any intravesical therapy * No prior treatment with bevacizumab or other angiogenesis inhibitors * No known history of brain metastases; brain imaging (magnetic resonance imaging \[MRI\]/computed tomography \[CT\]) is not required * No current congestive heart failure; New York Heart Association (NYHA) class II, III or…